Marinus Pharmaceuticals (MRNS) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free MRNS Stock Alerts $1.52 +0.02 (+1.33%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 5:21 PM | businesswire.comMarinus Pharmaceuticals Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the MRNS Class ActionJune 7 at 10:20 AM | businesswire.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Marinus Pharmaceuticals, Inc. with Losses to Contact the FirmJune 6 at 10:00 PM | globenewswire.comMARINUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmJune 6 at 8:00 PM | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNSJune 6 at 4:42 PM | prnewswire.comMRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 6 at 2:39 PM | globenewswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. (MRNS)June 6 at 2:36 PM | businesswire.comMRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 6 at 1:11 PM | globenewswire.comMARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.June 6 at 11:12 AM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Marinus Pharmaceuticals, Inc. - MRNSJune 6 at 11:06 AM | globenewswire.comClass Action Lawsuit Filed on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors – Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmJune 5, 2024 | globenewswire.comStockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Marinus Pharmaceuticals, Inc. (MRNS)June 5, 2024 | globenewswire.comMRNS INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNSJune 5, 2024 | businesswire.comEQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Marinus Pharmaceuticals, Inc. Investors – MRNSMay 28, 2024 | marketbeat.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and four have issuedMay 20, 2024 | msn.comMarinus Pharmaceuticals Completes Enrollment for Phase 3 Trial on Tuberous Sclerosis ComplexMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed: Marinus Pharmaceuticals’ Advancements and Long-term Patent Protection Signal Strong ProspectsMay 17, 2024 | businesswire.comMarinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex ProgramMay 11, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals Amidst Operational Progress and Strategic Cost ManagementMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on Marinus (MRNS)May 8, 2024 | washingtonpost.comMarinus Pharmaceuticals: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug TrialsMay 8, 2024 | msn.comMarinus Pharmaceuticals GAAP EPS of -$0.68 misses by $0.02, revenue of $7.68M misses by $1.48MMay 8, 2024 | msn.comMarinus Pharmaceuticals CEO to Speak at RBC Healthcare ConferenceMay 8, 2024 | finance.yahoo.comMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | businesswire.comMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Price Target Lowered to $11.00 at HC WainwrightHC Wainwright reduced their target price on shares of Marinus Pharmaceuticals from $27.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday.May 2, 2024 | marketbeat.comMarinus Pharmaceuticals (MRNS) Set to Announce Quarterly Earnings on WednesdayMarinus Pharmaceuticals (NASDAQ:MRNS) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 2, 2024 | businesswire.comMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceMay 1, 2024 | finance.yahoo.comMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024April 28, 2024 | marketbeat.comabrdn plc Acquires New Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)abrdn plc acquired a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 552,572 shares of the biopharmaceutical company's stock, valued at approximately $6,006,000. abrdn plcApril 24, 2024 | investing.comMarinus Pharmaceuticals Inc (MRNS)April 18, 2024 | marketbeat.comTruist Financial Trims Marinus Pharmaceuticals (NASDAQ:MRNS) Target Price to $10.00Truist Financial reduced their price target on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday.April 18, 2024 | marketbeat.comCantor Fitzgerald Comments on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued on Tuesday, April 16th. Cantor Fitzgerald analyst C. Duncan now forecasts that theApril 17, 2024 | msn.comBaird Downgrades Marinus Pharmaceuticals (MRNS)April 16, 2024 | msn.comRBC Capital Downgrades Marinus Pharmaceuticals (MRNS)April 16, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Neutral" at Robert W. BairdRobert W. Baird cut Marinus Pharmaceuticals from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $20.00 to $2.00 in a research report on Tuesday.April 15, 2024 | markets.businessinsider.comMaintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial HealthApril 15, 2024 | bizjournals.comMarinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidateApril 15, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Sector Perform" at Royal Bank of CanadaRoyal Bank of Canada downgraded Marinus Pharmaceuticals from an "outperform" rating to a "sector perform" rating and dropped their target price for the company from $24.00 to $3.00 in a report on Monday.April 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | markets.businessinsider.comMarinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionApril 15, 2024 | msn.comWhy Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?April 15, 2024 | investorplace.comWhy Are Stocks Up Today?April 15, 2024 | investorplace.comWhy Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?April 15, 2024 | marketwatch.comMarinus Pharmaceuticals' Trial of Therapy For Persistent Seizures Misses Early Stopping CriteriaApril 15, 2024 | businesswire.comMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsApril 15, 2024 | marketbeat.comTrading was temporarily halted for "MRNS" at 06:04 AM with a stated reason of "News pending."April 10, 2024 | marketbeat.comMarinus Pharmaceuticals' (MRNS) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday.April 9, 2024 | msn.comMarinus Pharmaceuticals Awards Stock Options to New Employees as Inducement Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. MRNS Media Mentions By Week MRNS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRNS News Sentiment▼0.000.75▲Average Medical News Sentiment MRNS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRNS Articles This Week▼133▲MRNS Articles Average Week Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RAPT Therapeutics News Today Puma Biotechnology News Today UroGen Pharma News Today Atea Pharmaceuticals News Today Q32 Bio News Today Kamada News Today XOMA News Today ESSA Pharma News Today Emergent BioSolutions News Today Inozyme Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRNS) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored